vimarsana.com
Home
Live Updates
FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Che
FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Che
FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma -November 16, 2023 at 05:41 pm EST
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Approval marks seventh...
Related Keywords
Canada ,
United States ,
,
Statement Of Merck Co Inc ,
Drug Administration ,
Facebook ,
Exchange Commission ,
Youtube ,
Patient Support Program ,
Instagram ,
Merck Access Program ,
Twitter ,
Linkedin ,
Merck Patient Support Program ,
Merck Co Inc ,
Selected Important Safety ,
Important Safety Information ,
Fatal Immune Mediated Adverse ,
Which Can Present With Diabetic ,
Nervous System ,
Connective Tissue ,
Patients With Multiple ,
Neck Squamous Cell ,
Bacillus Calmette Guerin Unresponsive ,
Mismatch Repair Deficient ,
Mismatch Repair Deficient Colorectal ,
Support Program ,
Looking Statement ,
Securities Litigation Reform Act ,
Annual Report ,
Markets ,